Holen Sie sich die Stockscreener-App
51.49
0.04%
0.02
Vorhandelsmarkt:
50.63
-0.86
-1.67%
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
FDA Letters Flag Oprah Video, Morgan Freeman Ad in Crackdown - Bloomberg.com
Weekly Recap: What is the Moat Score of BridgeBio Pharma IncShare Buyback & Low Risk Growth Stock Ideas - خودرو بانک
Aug Update: What is the PEG ratio of BridgeBio Pharma IncJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - خودرو بانک
Growth Review: Is BridgeBio Pharma Inc a speculative investmentJuly 2025 Macro Moves & Entry Point Confirmation Alerts - خودرو بانک
Insider Trends: Is AMCX exposed to currency risksDollar Strength & High Accuracy Buy Signal Tips - خودرو بانک
Achondroplasia Market Overview: Epidemiology, Treatment Landscape, Key Players | Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC - Barchart.com
Quarterly Trades: What are the future prospects of BridgeBio Pharma IncJuly 2025 Macro Moves & Verified Momentum Stock Ideas - خودرو بانک
HC Wainwright & Co. Reiterates Buy Rating on BBIO | BBIO Stock N - GuruFocus
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN
Zimmer Partners LP Has $10.42 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Baird Financial Group Inc. Acquires New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Woodline Partners LP Lowers Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO is Exome Asset Management LLC's 2nd Largest Position - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,053,600.00 in Stock - MarketBeat
Frank Mccormick Sells 74,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby - MSN
BridgeBio Pharma stock price target raised to $82 from $72 at UBS - Investing.com Canada
BBIO Stock: UBS Raises Price Target Amidst Continued Buy Rating | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Challenges Pfizer's ATTR-CM Promotion Tactics - GuruFocus
UBS Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $82 - 富途牛牛
Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg - Seeking Alpha
Fred Alger Management LLC Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Alliancebernstein L.P. Has $92.79 Million Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
UBS Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Adage Capital Partners GP L.L.C. Purchases 246,555 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Philosophy Capital Management LLC Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race - Bloomberg.com
Jefferies Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio stock maintains Buy rating at UBS ahead of key trial data - Investing.com Canada
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $58 - 富途牛牛
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $58 to $76 - 富途牛牛
Bosun Asset Management LLC Takes $412,000 Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Optimistic Buy Rating for BridgeBio Pharma: Promising ADH1 Treatment and Market Potential - TipRanks
238,168 Shares: BridgeBio Pharma's Major Employee Stock Grants Signal Growth Push in Genetic Disease Research - Stock Titan
BridgeBio Pharma stock maintains Buy rating at Jefferies on encaleret potential - Investing.com Canada
Transcript : BridgeBio Pharma, Inc.Special Call - MarketScreener
Cutter Capital Management LP Reduces Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio says new Attruby data adds to benefit in ATTR-CM - MSN
Cormorant Asset Management LP Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Kumar, BridgeBio Pharma CEO, sells $4.1m in BBIO stock By Investing.com - Investing.com South Africa
Kumar, BridgeBio Pharma CEO, sells $4.1m in BBIO stock - Investing.com
Will BridgeBio Pharma Inc. benefit from government policyPortfolio Risk Report & High Conviction Trade Alerts - classian.co.kr
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $68 - 富途牛牛
BridgeBio Pharma Inc. Price Holds Above Key Fib Level2025 Year in Review & Risk Adjusted Swing Trade Ideas - beatles.ru
BridgeBio’s Phase 2 hypoparathyroidism data; FDA clears second pig kidney trial - Endpoints News
BridgeBio Pharma (BBIO): Assessing Valuation After Strong Encaleret Data and Pipeline Advances - Yahoo Finance
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $60 - 富途牛牛
BridgeBio Pharma’s Encaleret: Promising Developments and Potential Market Impact - TipRanks
0.77%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):